Drug Profile
Ruzinurad - Jiangsu Hengrui Medicine Co.
Alternative Names: SHR 4640Latest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antigouts; Bromobenzenes; Carboxylic acids; Cyclobutanes; Quinolines; Small molecules; Uricosurics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gout
- Phase II Hyperuricaemia
Most Recent Events
- 16 Feb 2024 Jiangsu HengRui Medicine completes a phase I trial for Gout and Hyperuricemia (In volunteers) in China (PO) (NCT06196580)
- 04 Jan 2024 Jiangsu HengRui Medicine initiates a phase I trial for Gout and Hyperuricemia (In volunteers) in China (PO) (NCT06196580)
- 04 Jan 2024 Jiangsu HengRui Medicine plans a phase I trial for pharmacokinetics and QT interval study (In Volunteers) at unknown location (PO) (NCT06196580)